VRDN Profile
Viridian Therapeutics, Inc., a biotechnology firm based in Waltham, Massachusetts, specializes in developing innovative treatments for severe and often underserved diseases. The company’s primary focus is on advanced therapeutic antibodies designed to target specific disease mechanisms. Its lead candidate, VRDN-001, is a humanized monoclonal antibody aimed at inhibiting insulin-like growth factor 1 receptor (IGF-1R). This drug is currently undergoing Phase 1/2 clinical trials for the treatment of thyroid eye disease (TED), a debilitating condition characterized by inflammation and swelling of the eyes.
In addition to VRDN-001, Viridian is advancing VRDN-002, another IGF-1R antibody currently in Phase 1 clinical trials. This compound is being investigated for its potential to offer therapeutic benefits in treating TED. VRDN-003, a third therapeutic antibody developed by the company, also targets IGF-1R and is designed specifically for the treatment of TED. Each of these antibodies represents a critical component of Viridian’s strategy to address significant medical needs in the realm of rare and complex diseases.
Formerly known as Miragen Therapeutics, Inc., the company rebranded to Viridian Therapeutics, Inc. in January 2021 to better reflect its renewed focus and strategic direction. Founded in 2006, Viridian has evolved its business model and pipeline to concentrate on high-impact therapeutic areas, leveraging its expertise in antibody development to bring novel treatments to market.
Viridian Therapeutics operates at the forefront of biotechnology innovation, utilizing cutting-edge research to develop therapies with the potential to transform patient care. With its strong emphasis on IGF-1R-targeted treatments and ongoing clinical trials, the company is poised to make significant contributions to the field of therapeutic development for serious and rare conditions.
|
